Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?

Show full item record



Permalink

http://hdl.handle.net/10138/223961

Citation

Eriksson , M , Reichardt , P , Hall , K S , Schutte , J , Cameron , S , Hohenberger , P , Bauer , S , Leinonen , M , Reichardt , A , Davis , M R , Alvegard , T & Joensuu , H 2016 , ' Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence? ' , European Journal of Cancer , vol. 59 , pp. 128-133 . https://doi.org/10.1016/j.ejca.2016.02.021

Title: Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Author: Eriksson, Mikael; Reichardt, Peter; Hall, Kirsten Sundby; Schutte, Jochen; Cameron, Silke; Hohenberger, Peter; Bauer, Sebastian; Leinonen, Mika; Reichardt, Annette; Davis, Maria Rejmyr; Alvegard, Thor; Joensuu, Heikki
Contributor: University of Helsinki, Clinicum
Date: 2016-05
Language: eng
Number of pages: 6
Belongs to series: European Journal of Cancer
ISSN: 0959-8049
URI: http://hdl.handle.net/10138/223961
Abstract: Purpose: Preoperative percutaneous transabdominal wall biopsy may be considered to diagnose gastrointestinal stromal tumour (GIST) and plan preoperative treatment with tyrosine kinase inhibitors when an endoscopic biopsy is not possible. Hypothetically, a transabdominal wall biopsy might lead to cell seeding and conversion of a local GIST to a disseminated one. We investigated the influence of preoperative needle biopsy on survival outcomes. Methods: We collected the clinical data from hospital case records of the 397 patients who participated in the Scandinavian Sarcoma Group (SSG) XVIII/Arbeitsgemeinschaft Internistische Onkologie (AIO) randomised trial and who had a transabdominal fine needle and/or core needle biopsy carried out prior to study entry. The SSG XVIII/AIO trial compared 1 and 3 years of adjuvant imatinib in a patient population with a high risk of GIST recurrence after macroscopically radical surgery. The primary end-point was recurrence-free survival (RFS), and the secondary end-points included overall survival (OS). Results: A total of 47 (12.0%) out of the 393 patients with data available underwent a percutaneous biopsy. No significant difference in RFS or OS was found between the patients who underwent or did not undergo a percutaneous biopsy either in the entire series or in subpopulation analyses, except for a statistically significant RFS advantage for patients who had a percutaneous biopsy and a tumour >= 10 cm in diameter. Conclusion: A preoperative diagnostic percutaneous biopsy of a suspected GIST may not increase the risk for GIST recurrence in a patient population who receive adjuvant imatinib after the biopsy. (C) 2016 Elsevier Ltd. All rights reserved.
Subject: Gastrointestinal stromal tumour
GIST
Needle biopsy
Imatinib
Adjuvant
Risk of recurrence
CLINICAL-PRACTICE GUIDELINES
FOLLOW-UP
IMATINIB
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0959804916001386_main.pdf 453.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record